CorMedix (CRMD) Stock: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.19
-0.23 (-3.10%)
âŧ
5d:
-8.41%
30d:
-16.49%
90d:
-18.2%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 40.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRMD is fairly priced but lacks strong directional signals. At 40.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.19, which is considered slightly low relative to its 30-day fair value range of $7.80 to $8.37. From a valuation perspective, the stock is trading at a premium (Forward PE: 126.8) compared to its historical average (45.6). At these levels, the market is pricing in 40.7% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a downtrend. The price is currently testing key support at $7.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $15.33 (+113.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRMD is in a downtrend. The price is currently testing key support at $7.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $15.33 (+113.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.80 -
$8.37
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 113.3% below Wall St target ($15.33)
- BEARISH: Market expects 40.7% growth - appears too optimistic based on history
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.80 -
$8.37
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.17
Resistance Level
$8.19
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
126.81
Wall Street Target
$15.33
(+113.3%)
Revenue Growth (YoY)
156.5%
Earnings Growth (YoY)
6.7%
Profit Margin
40.5%
Valuation Premium vs History
+40.7% premium
PE vs Historical
126.8 vs 45.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+40.7%
(market-implied from PE analysis)
1-Year Target
$10.12
(+41%)
2-Year Target
$14.23
(+98%)
3-Year Target
$20.03
(+179%)
3-Yr Target (if PE normalizes)
(PE: 127â46)
PE COMPRESSION
$7.20
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 126.8, Growth: -88.5%)
$5.24
(+-27%)
Base:
(SPY PE: 20.4, Growth: -88.5%)
$0.84
(-88%)
Bear:
(PE: 17.3, Growth: -88.5%)
$0.72
(-90%)
đ
Valuation based on Current Earnings
Trailing PE: 3.40 | Current EPS (TTM): $2.18
Bull Case
$4.08
(-43%)
Analyst growth -50.0%, PE expands to 3.7
Base Case
$3.71
(-48%)
Market implied -50.0%, PE stable at 3.4
Bear Case
$5.05
(-30%)
Severe decline -20.0%, PE contracts to 2.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 04, 2026 11:48 AM ET
Data refreshes hourly during market hours. Next update: 12:48 PM
Data refreshes hourly during market hours. Next update: 12:48 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$294 | 67 BUY |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
19 analysts |
$644 | 67 BUY |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
27 analysts |
$853 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$32 | 62 BUY |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
13 analysts |
$74 | 66 BUY |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
